- Home
- Automated
- List of product information
- INFLUVAC TETRA, SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE 0.5 ML [SIN15591P]
INFLUVAC TETRA, SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE 0.5 ML [SIN15591P]
Active ingredients: INFLUVAC TETRA, SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE 0.5 ML
Last updated 26 October 2025
Product Info
INFLUVAC TETRA, SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE 0.5 ML
[SIN15591P]
Product information
Active Ingredient and Strength | INFLUENZA VIRUS (SH) A/CROATIA/10136RV/2023 (H3N2)-LIKE STRAIN (A/CROATIA/10136RV/2023, X-425A) - 15 MICROGRAMS HA/0.5 ML |
Dosage Form | INJECTION, SUSPENSION |
Manufacturer and Country | ABBOTT BIOLOGICALS B.V. - NETHERLANDS |
Registration Number | SIN15591P |
Licence Holder | ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | J07BB02 |
4.1. Therapeutic indications
Prophylaxis of influenza, especially those who run an increased risk of associated complications.
Influvac® Tetra is indicated in adults and children from 6 months of age.
The use of Influvac® Tetra should be based on official recommendations.
4.2. Posology and method of administration
Posology
Adults: 0.5 ml.
Pediatric patients
Children from 6 months to 17 years of age: 0.5 ml.
Children less than 9 years of age, who have not previously been vaccinated with a seasonal influenza vaccine: a second dose of 0.5 ml should be given after an interval of at least 4 weeks.
Infants less than 6 months of age: the safety and efficacy of Influvac® Tetra in infants have not been established.
Method of Administration
Immunization should be carried out by intramuscular or deep subcutaneous injection. The preferred sites for intramuscular injection are the anterolateral aspect of the thigh (or the deltoid muscle if muscle mass is adequate) in children 6 months through 35 months of age, or the deltoid muscle in children from 36 months of age and adults.
Precautions to be taken before handling or administrating the medicinal product:
For instructions for preparation of the medicinal product before administration, see section 6.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
4.3. Contraindications
Hypersensitivity to the active substances, to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information or to any component that may be present as traces such as eggs (ovalbumin, chicken proteins), formaldehyde, cetyltrimethylammonium bromide, polysorbate 80 or gentamicin.
Immunization shall be postponed in patients with febrile illness or acute infection.